Table 2 Correlation between the expression of CYP24A1 and the clinicopathologic characteristics in breast cancer.
From: Low CYP24A1 mRNA expression and its role in prognosis of breast cancer
Clinical characteristics | Variable | Number | CYP24A1 mRNA | χ2 | P value | |
|---|---|---|---|---|---|---|
High n (%) | Low n (%) | |||||
Age | <60 | 589 | 394 (60.99) | 195 (42.76) | 35.6946 | 0.0005 |
≥60 | 513 | 252 (39.01) | 261 (57.24) |  |  | |
Gender | Female | 1090 | 643 (99.54) | 447 (98.03) | 5.6535 | 0.0175 |
Male | 12 | 3 (0.46) | 9 (1.97) | Â | Â | |
Histological type | Infiltrating Ductal Carcinoma | 790 | 448 (69.46) | 342 (75) | 6.7469 | 0.034 |
Infiltrating Lobular Carcinoma | 204 | 136 (21.09) | 68 (14.91) | Â | Â | |
Other | 107 | 61 (9.46) | 46 (10.09) | Â | Â | |
Molecular subtype | Basal | 142 | 119 (24.64) | 23 (6.28) | 99.1391 | 0.0005 |
Her2 | 67 | 25 (5.18) | 42 (11.48) | Â | Â | |
LumA | 422 | 255 (52.8) | 167 (45.63) | Â | Â | |
LumB | 194 | 66 (13.66) | 128 (34.97) | Â | Â | |
Normal | 24 | 18 (3.73) | 6 (1.64) | Â | Â | |
ER | Indeterminate | 2 | 0 (0) | 2 (0.46) | 22.9524 | 0.0005 |
Negative | 239 | 170 (27.6) | 69 (15.75) | Â | Â | |
Positive | 813 | 446 (72.4) | 367 (83.79) | Â | Â | |
PR | Indeterminate | 4 | 2 (0.33) | 2 (0.46) | 3.8 | 0.1169 |
Negative | 345 | 216 (35.12) | 129 (29.45) | Â | Â | |
Positive | 704 | 397 (64.55) | 307 (70.09) | Â | Â | |
HER2 | Equivocal | 180 | 100 (18.59) | 80 (20.89) | 24.8705 | 0.0005 |
Indeterminate | 12 | 5 (0.93) | 7 (1.83) | Â | Â | |
Negative | 565 | 362 (67.29) | 203 (53) | Â | Â | |
Positive | 164 | 71 (13.2) | 93 (24.28) | Â | Â | |
Menopause status | Inde | 34 | 23 (3.91) | 11 (2.6) | 15.7947 | 0.0005 |
Peri | 40 | 27 (4.59) | 13 (3.07) | Â | Â | |
Post | 706 | 382 (64.97) | 324 (76.6) | Â | Â | |
Pre | 231 | 156 (26.53) | 75 (17.73) | Â | Â | |
T classification | T1 | 281 | 179 (27.71) | 102 (22.37) | 5.2863 | 0.2354 |
T2 | 640 | 363 (56.19) | 277 (60.75) | Â | Â | |
T3 | 138 | 82 (12.69) | 56 (12.28) | Â | Â | |
T4 | 40 | 20 (3.1) | 20 (4.39) | Â | Â | |
TX | 3 | 2 (0.31) | 1 (0.22) | Â | Â | |
N classification | N0 | 516 | 310 (47.99) | 206 (45.18) | 13.4385 | 0.0085 |
N1 | 367 | 226 (34.98) | 141 (30.92) | Â | Â | |
N2 | 120 | 67 (10.37) | 53 (11.62) | Â | Â | |
N3 | 79 | 37 (5.73) | 42 (9.21) | Â | Â | |
NX | 20 | 6 (0.93) | 14 (3.07) | Â | Â | |
M classification | M0 | 917 | 536 (82.97) | 381 (83.55) | 2.0835 | 0.3573 |
M1 | 22 | 10 (1.55) | 12 (2.63) | Â | Â | |
MX | 163 | 100 (15.48) | 63 (13.82) | Â | Â | |
Stage | I | 182 | 117 (18.22) | 65 (14.38) | 6.4159 | 0.1599 |
II | 626 | 372 (57.94) | 254 (56.19) | Â | Â | |
III | 252 | 137 (21.34) | 115 (25.44) | Â | Â | |
IV | 20 | 9 (1.4) | 11 (2.43) | Â | Â | |
X | 14 | 7 (1.09) | 7 (1.55) | Â | Â | |
Lymph node status | NO | 28 | 13 (3.02) | 15 (5.08) | 2.0026 | 0.1699 |
YES | 697 | 417 (96.98) | 280 (94.92) | Â | Â | |
Margin status | Close | 31 | 20 (3.31) | 11 (2.58) | 2.6135 | 0.2599 |
Negative | 922 | 545 (90.08) | 377 (88.29) | Â | Â | |
Positive | 79 | 40 (6.61) | 39 (9.13) | Â | Â | |
Vital status | Deceased | 155 | 69 (10.68) | 86 (18.86) | 14.7927 | 0.0005 |
Living | 947 | 577 (89.32) | 370 (81.14) | Â | Â | |
Radiation therapy | NO | 445 | 253 (42.59) | 192 (47.06) | 1.9543 | 0.1864 |
YES | 557 | 341 (57.41) | 216 (52.94) | Â | Â | |
Neoadjuvant treatment | NO | 1088 | 641 (99.38) | 447 (98.03) | 4.1944 | 0.045 |
YES | 13 | 4 (0.62) | 9 (1.97) | Â | Â | |
Targeted molecular therapy | NO | 46 | 24 (7.02) | 22 (9.28) | 0.9821 | 0.3538 |
YES | 533 | 318 (92.98) | 215 (90.72) | Â | Â | |
Sample type | Metastatic | 7 | 4 (0.62) | 3 (0.66) | 0.0062 | 1 |
Primary Tumor | 1097 | 643 (99.38) | 454 (99.34) | Â | Â | |
Overall survival | NO | 933 | 568 (89.31) | 365 (80.93) | 15.2275 | 0.001 |
YES | 154 | 68 (10.69) | 86 (19.07) | Â | Â | |
Recurrence-free survival | NO | 816 | 509 (92.21) | 307 (85.28) | 11.1183 | 0.0005 |
YES | 96 | 43 (7.79) | 53 (14.72) | Â | Â | |
